Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

5.45
Delayed Data
As of Jun 18
 -0.11 / -1.97%
Today’s Change
3.12
Today|||52-Week Range
9.00
+65.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$224.8M

Company Description

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Contact Information

Zynerba Pharmaceuticals, Inc.
80 West Lancaster Avenue
Devon Pennsylvania 19333
P:(484) 581-7505
Investor Relations:
(484) 581-7483

Employees

Shareholders

Individual stakeholders6.02%
Mutual fund holders17.21%
Other institutional11.14%

Top Executives

Armando AnidoChairman & Chief Executive Officer
Terri B. SebreePresident
James E. FickenscherChief Financial Officer & VP-Corporate Development
Nancy TichVice President-Clinical
Joseph M. PalumboChief Medical Office & Vice President